Medical Aesthetic Platform Gengmei App Completes Tens of Millions USD Series D1 Funding and Files IPO Prospectus
As a leading platform in the internet-based medical aesthetics sector, Gengmei App has drawn sustained industry attention to its fundraising progress since announcing its Series C financing in the summer of 2016. VCBeat (WeChat ID: vcbeat) reporters have learned from multiple independent sources within the medical aesthetics industry and the venture capital community that Gengmei App completed its Series D1 financing round in July, with investors including listed companies and seasoned fund-of-funds players in the industry.
Previous reports have shown that the Gengmei App is a leading global medical aesthetics and health service platform. Users can purchase high-quality, affordable, and secure consumer medical services within the app, such as plastic surgery, minimally invasive procedures, dentistry, ophthalmology, and anti-aging treatments. Additionally, users can share their beauty enhancement experiences with others in the community and receive one-on-one online consultations and services from doctors.
Liu Di, Founder and CEO of Gengmei, graduated from Renmin University of China. He previously served as Co-Founder of Chunyu Yisheng (Spring Rain Doctor) and Founder of a rare disease medical community. Gengmei’s previous investors include Matrix Partners, Sequoia Capital, Tencent, CHJ Jewellery, Vivo Capital, China Securities Co., Ltd., Fosun Group, and Legend Capital.
Related Reading: